In the EXAMINE trial, alogliptin (a DPP4 inhibitor) use was associated with increased admissions for HF in T2DM patients with recent acute coronary syndromes, but the differences were not significant: HR 1.19 (95% CI: 0.89–1.58), p = 0.24. The gene discussed is DPP4; the disease is acute coronary syndrome.